What is the expected growth forecast for the Transthyretin Amyloidosis Drug market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driving future outlook.

What are the key drivers of the Transthyretin Amyloidosis Drug market?

Key drivers include increasing disease prevalence and rising demand for effective treatments.

What are the major challenges facing the Transthyretin Amyloidosis Drug market?

Challenges include high development costs and stringent regulatory requirements.

Which regions are leading the Transthyretin Amyloidosis Drug market?

North America and Europe are currently the regional leaders in the market.

Who are the top companies in the Transthyretin Amyloidosis Drug market?

Top companies include Pfizer, Johnson & Johnson, and Novartis, driving market growth.

What future opportunities exist in the Transthyretin Amyloidosis Drug market?

Future opportunities include emerging markets and innovative technologies, shaping the market's future outlook.

How is technology impacting the Transthyretin Amyloidosis Drug market?

Technology is advancing diagnosis and treatment options, improving patient outcomes and market growth.

What is the current regulatory landscape for the Transthyretin Amyloidosis Drug market?

The regulatory landscape is evolving, with ongoing updates to guidelines and approvals, affecting market size.

How will the regulatory landscape influence the Transthyretin Amyloidosis Drug market's future outlook?

The regulatory landscape will impact market growth, with ongoing changes shaping the future of the Transthyretin Amyloidosis Drug market.

Transthyretin Amyloidosis Drug Market Intelligence Report 2026 — Updated June 2026

Transthyretin Amyloidosis Drug by Application (Hereditary Transthyretin Amyloidosis, Wild Transthyretin Amyloidosis), by Types (Tafamidis, Patisiran, Inotersen, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $5449 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $5449 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Transthyretin Amyloidosis Drug Market Size | CAGR 7.5% Forecast 2033

Transthyretin Amyloidosis Drug Market Intelligence Report 2026 — Updated June 2026

🏭 Healthcare🌍 Global

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $5449 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $5449 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Transthyretin Amyloidosis Drug Market Overview

The Transthyretin Amyloidosis Drug market refers to the global industry focused on developing and marketing medications for the treatment of Transthyretin Amyloidosis, a rare genetic disorder. As the growth outlook for this market continues to evolve, it is essential to examine the Transthyretin Amyloidosis Drug market size, market forecast, and industry expansion. The scope of this market encompasses various synonyms such as Amyloidosis treatments and Transthyretin-related medications. The current Transthyretin Amyloidosis Drug market size is approximately $1.4 billion. The market is expected to experience a significant growth forecast, with a compound annual growth rate (CAGR) of around 10%, driven by macro drivers such as increasing disease awareness, advancements in medical technology, and rising healthcare expenditures.

Loading chart…

The Transthyretin Amyloidosis Drug market is shaped by several key forces, including technology shifts towards gene therapies and RNA-targeting treatments, regulations governing rare disease treatments, and competitive intensity among pharmaceutical companies. The largest region for this market is North America, while the fastest-growing region is expected to be Asia-Pacific. As the market continues to expand, it is crucial for C-suite, strategic planners, and BD teams to stay informed about the latest developments and trends in the Transthyretin Amyloidosis Drug market.

Report Overview

Report Attribute	Details
Market size value in 2025	5.45 billion
Revenue forecast in 2033	9.50 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Pfizer Inc; AstraZeneca; Prothena Corporation plc; Ionis Pharmaceuticals; BELLUS Health Inc; Alnylam Pharmaceuticals, Inc; Eidos Therapeutics, Inc; SOM BIOTECH; Abbvie, Inc; Bausch Health Companies Inc; Bristol Myers Squibb Company; GSK Plc; Merck KGaA; Sanofi
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Transthyretin Amyloidosis Drug market is poised for significant growth, driven by increasing demand for effective treatments and a rising patient population. This section delves into the market dynamics shaping the Transthyretin Amyloidosis Drug market size and growth forecast.

Growth Drivers2 items

Advances in gene therapy and RNA-targeting therapies are expanding treatment options, driving growth in the Transthyretin Amyloidosis Drug market. These innovative approaches are improving patient outcomes, thereby increasing demand for these drugs.

Government initiatives and regulatory support are facilitating the development and approval of Transthyretin Amyloidosis drugs, contributing to the market's growth forecast. This support is critical in addressing the unmet medical needs of patients with this rare and debilitating disease.

Restraints2 items

High development costs and the complexity of clinical trials for Transthyretin Amyloidosis drugs are significant restraints on the market. These factors can limit the number of drugs in development and slow the pace of innovation.

The patent expiration of key drugs can lead to increased competition from generics, potentially reducing revenue for pharmaceutical companies and impacting the Transthyretin Amyloidosis Drug market size. This shift can alter the market landscape and force companies to adapt their strategies.

Opportunities2 items

The growing awareness of Transthyretin Amyloidosis and its treatment options among healthcare professionals and patients presents opportunities for market expansion. Educational initiatives and advocacy efforts can increase diagnosis rates and drive demand for effective treatments.

The emerging markets in Asia and Latin America offer significant opportunities for growth in the Transthyretin Amyloidosis Drug market. As these economies grow, so does their demand for advanced healthcare solutions, including treatments for rare diseases like Transthyretin Amyloidosis.

Challenges2 items

The complexity of diagnosis and the lack of standardized diagnostic criteria for Transthyretin Amyloidosis pose significant challenges for the market. These issues can lead to underdiagnosis and misdiagnosis, affecting the growth forecast of the Transthyretin Amyloidosis Drug market.

The need for long-term treatment and the high cost of Transthyretin Amyloidosis drugs can be a barrier to access for many patients, impacting the market's potential for growth. Payers and pharmaceutical companies must work together to find solutions that balance affordability with the need for profitable investment in drug development.

Market Segmentation

Loading chart…

The Transthyretin Amyloidosis Drug market can be segmented based on Application, which refers to the specific use of the drug in treating various forms of transthyretin amyloidosis. This segmentation is crucial in understanding the Transthyretin Amyloidosis Drug segmentation as it highlights the different areas where these drugs are applied, contributing to the overall market size. The application segment includes subtypes such as treating familial amyloid polyneuropathy (FAP), familial amyloid cardiomyopathy (FAC), and wild-type amyloidosis, among others.

Another key segment in the Transthyretin Amyloidosis Drug market is Types, which encompasses the various kinds of drugs used to treat transthyretin amyloidosis. This includes subtypes such as tafamidis, patisiran, and inotersen, among others. Understanding the types of drugs available is essential for market taxonomy as it helps in identifying the competitive landscape and the potential for growth in specific drug categories, ultimately contributing to the overall Transthyretin Amyloidosis Drug market size.

Transthyretin Amyloidosis Drug Segmentation Breakdown8 items

Application

Hereditary Transthyretin Amyloidosis

Wild Transthyretin Amyloidosis

Types

Tafamidis

Patisiran

Inotersen

Other

Regional Insights

Loading chart…

The Transthyretin Amyloidosis Drug market growth is anticipated to be driven by various regional factors. North America is the largest region, accounting for approximately 40% of the market share, due to high adoption rates of novel therapeutics, favorable policies supporting research and development, and significant investments in healthcare infrastructure. Key drivers in North America include increasing demographic awareness, advancements in diagnostic technologies, and a mature ecosystem that supports clinical trials and drug development.

Asia Pacific is the fastest-growing region, with a growth rate driven by expanding healthcare infrastructure, growing demand for effective treatments, and government initiatives to improve access to care. Europe, with its established healthcare system and high disease prevalence, accounts for around 30% of the market share. Latin America and Middle East & Africa, though smaller, are expected to witness growth due to increasing awareness and improving economic conditions.

The regional forecast indicates that these trends will continue, with North America maintaining its lead and Asia Pacific driving the Transthyretin Amyloidosis Drug market growth. Key factors influencing the market include adoption of new treatments, policies supporting innovation, and investments in research and development. Understanding these regional dynamics is crucial for stakeholders to navigate the complex landscape of the Transthyretin Amyloidosis Drug market.

Competitive Landscape

The Transthyretin Amyloidosis Drug market is moderately consolidated, driven by a mix of global players and local companies. The Transthyretin Amyloidosis Drug competitive landscape is characterized by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players focus on product innovation and regulatory approvals to maintain their market position, while local companies emphasize distribution and pricing strategies to compete.

Companies in this market employ various strategies, including M&A, partnerships, product launches, expansion, R&D, and localization, to differentiate themselves. Competitive differentiation is achieved through technology, service model, channel strength, customization, and cost advantages. However, companies face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. The following companies have adopted distinct strategic focuses:

Pfizer Inc: regional expansion

AstraZeneca: innovation pipeline

Prothena Corporation plc: premium pricing

Ionis Pharmaceuticals: OEM tie-ups

BELLUS Health Inc: local manufacturing

Alnylam Pharmaceuticals, Inc: vertical integration

Key Transthyretin Amyloidosis Drug Companies14 items

Pfizer Inc

AstraZeneca

Prothena Corporation plc

Ionis Pharmaceuticals

BELLUS Health Inc

Alnylam Pharmaceuticals, Inc

Eidos Therapeutics, Inc

SOM BIOTECH

Abbvie, Inc

Bausch Health Companies Inc

Bristol Myers Squibb Company

GSK Plc

Merck KGaA

Sanofi

Market Ecosystem

The Transthyretin Amyloidosis Drug ecosystem encompasses a complex network of participants, spanning from upstream technology providers and suppliers to downstream end users. This ecosystem can be broadly segmented into three main stages: upstream, midstream, and downstream, with value being created and captured at each stage. The upstream stage involves technology providers and suppliers, while the midstream stage consists of integrators and manufacturers, and the downstream stage comprises channels and end users. Understanding the Transthyretin Amyloidosis Drug ecosystem through a value chain analysis is crucial for identifying key interactions and relationships between participants.

Raw material/component suppliers — providing active pharmaceutical ingredients

Technology providers — developing novel drug delivery systems

OEMs / manufacturers — producing Transthyretin Amyloidosis Drugs

Distributors / channel partners — facilitating drug distribution

Service providers / after-sales — offering patient support services

End users / buyers — receiving treatment for Transthyretin Amyloidosis

Regulators/standards bodies — overseeing drug approvals and compliance

In the Transthyretin Amyloidosis Drug ecosystem, control points are largely influenced by regulators and standards bodies, who oversee drug approvals and compliance. Dependency risks arise from input constraints, such as the availability of active pharmaceutical ingredients, and standards, including stringent regulatory requirements. Switching costs and partnerships are also significant, as manufacturers often rely on specific suppliers and distributors. Furthermore, the ecosystem differs by region, with varying regulatory frameworks and market access requirements. Understanding these dynamics is essential for navigating the complex Transthyretin Amyloidosis Drug ecosystem.

Recent Industry Insights

The Transthyretin Amyloidosis Drug industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships, such as the collaboration between pharmaceutical companies to develop novel therapies, have been a key highlight. Additionally, there have been notable mergers and acquisitions, including the acquisition of a biotech firm specializing in amyloidosis treatments. Product launches, such as the introduction of a new oral medication for transthyretin amyloidosis, have also been observed. Furthermore, regulatory changes, including the approval of new treatment guidelines, have impacted the industry. A shift in consumer trends towards personalized medicine has also been noted, driving innovation in the Transthyretin Amyloidosis Drug market.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Transthyretin Amyloidosis Drug market outlook. The market exhibits moderate attractiveness, driven by the increasing prevalence of transthyretin amyloidosis and the growing demand for effective treatments. The competitive intensity is relatively high, with several key players investing heavily in research and development.

The long-term outlook for the market is promising, with innovative therapies and treatments in the pipeline. However, the demand-supply balance is a concern, with potential shortages of certain drugs. Key risk factors include regulatory challenges, patent expirations, and intense competition. Overall, the market is expected to experience steady growth, driven by the need for effective treatments and the increasing awareness of transthyretin amyloidosis.

11 items

1. Executive Summary

2. Transthyretin Amyloidosis Drug Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Transthyretin Amyloidosis Drug Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Transthyretin Amyloidosis Drug Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hereditary Transthyretin Amyloidosis

6.1.2. Wild Transthyretin Amyloidosis

6.2. Global Transthyretin Amyloidosis Drug Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Tafamidis

6.2.2. Patisiran

6.2.3. Inotersen

6.2.4. Other

6.3. Global Transthyretin Amyloidosis Drug Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Transthyretin Amyloidosis Drug Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Transthyretin Amyloidosis Drug Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Transthyretin Amyloidosis Drug Market Competition by Key Manufacturers

8.1. Global Transthyretin Amyloidosis Drug Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Transthyretin Amyloidosis Drug: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Pfizer Inc

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. AstraZeneca

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Prothena Corporation plc

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Ionis Pharmaceuticals

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. BELLUS Health Inc

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Alnylam Pharmaceuticals, Inc

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Eidos Therapeutics, Inc

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. SOM BIOTECH

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Abbvie, Inc

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Bausch Health Companies Inc

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Bristol Myers Squibb Company

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. GSK Plc

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Merck KGaA

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Sanofi

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Transthyretin Amyloidosis Drug Market

Figure 4: Global Transthyretin Amyloidosis Drug Market: Drivers

Figure 5: Global Transthyretin Amyloidosis Drug Market: Challenges

Figure 6: Global Transthyretin Amyloidosis Drug Market: Trends

Figure 7: Global Transthyretin Amyloidosis Drug Market: Opportunity

Figure 8: Global Transthyretin Amyloidosis Drug Market: Restraint

Figure 9: Global Transthyretin Amyloidosis Drug Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Transthyretin Amyloidosis Drug Market Value (USD Million) By Region

Figure 15: Global Transthyretin Amyloidosis Drug Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Transthyretin Amyloidosis Drug Market Value (USD Million) By Region

Figure 23: Global Transthyretin Amyloidosis Drug Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

81 items

Table 1: Market Segmentation Analysis

Table 2: Global Transthyretin Amyloidosis Drug Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Transthyretin Amyloidosis Drug Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Transthyretin Amyloidosis Drug Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Transthyretin Amyloidosis Drug Market Value (USD Million) By Region

Table 10: Global Transthyretin Amyloidosis Drug Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Transthyretin Amyloidosis Drug Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Transthyretin Amyloidosis Drug Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Transthyretin Amyloidosis Drug Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Pfizer Inc Basic Information And Sales Area

Table 31: Pfizer Inc. Products Portfolio

Table 32: AstraZeneca Basic Information And Sales Area

Table 33: AstraZeneca. Products Portfolio

Table 34: Prothena Corporation plc Basic Information And Sales Area

Table 35: Prothena Corporation plc. Products Portfolio

Table 36: Ionis Pharmaceuticals Basic Information And Sales Area

Table 37: Ionis Pharmaceuticals. Products Portfolio

Table 38: BELLUS Health Inc Basic Information And Sales Area

Table 39: BELLUS Health Inc. Products Portfolio

Table 40: Alnylam Pharmaceuticals, Inc Basic Information And Sales Area

Table 41: Alnylam Pharmaceuticals, Inc. Products Portfolio

Table 42: Eidos Therapeutics, Inc Basic Information And Sales Area

Table 43: Eidos Therapeutics, Inc. Products Portfolio

Table 44: SOM BIOTECH Basic Information And Sales Area

Table 45: SOM BIOTECH. Products Portfolio

Table 46: Abbvie, Inc Basic Information And Sales Area

Table 47: Abbvie, Inc. Products Portfolio

Table 48: Bausch Health Companies Inc Basic Information And Sales Area

Table 49: Bausch Health Companies Inc. Products Portfolio

Table 50: Bristol Myers Squibb Company Basic Information And Sales Area

Table 51: Bristol Myers Squibb Company. Products Portfolio

Table 52: GSK Plc Basic Information And Sales Area

Table 53: GSK Plc. Products Portfolio

Table 54: Merck KGaA Basic Information And Sales Area

Table 55: Merck KGaA. Products Portfolio

Table 56: Sanofi Basic Information And Sales Area

Table 57: Sanofi. Products Portfolio

Table 58: Global Market Value (USD Million) (2025-2032) By Application

Table 59: Global Market Share (%) By Application (2032)

Table 60: Global Market Value (USD Million) (2025-2032) By Types

Table 61: Global Market Share (%) By Types (2032)

Table 62: Global Transthyretin Amyloidosis Drug Market Value (USD Million) By Region

Table 63: Global Transthyretin Amyloidosis Drug Market Share (%) By Region (2025-2032)

Table 64: North America Market Value (USD Million) (2025-2032) By Country

Table 65: North America Market Value (USD Million) (2025-2032) By Application

Table 66: North America Market Value (USD Million) (2025-2032) By Types

Table 67: Europe Market Value (USD Million) (2025-2032) By Country

Table 68: Europe Market Value (USD Million) (2025-2032) By Application

Table 69: Europe Market Value (USD Million) (2025-2032) By Types

Table 70: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 71: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 72: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 73: South America Market Value (USD Million) (2025-2032) By Country

Table 74: South America Market Value (USD Million) (2025-2032) By Application

Table 75: South America Market Value (USD Million) (2025-2032) By Types

Table 76: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 77: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 78: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 79: Research Programs/Design For This Report

Table 80: Key Data Information From Secondary Sources

Table 81: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Transthyretin Amyloidosis Drug Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	5.45 billion
Revenue forecast in 2033	9.50 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Pfizer Inc; AstraZeneca; Prothena Corporation plc; Ionis Pharmaceuticals; BELLUS Health Inc; Alnylam Pharmaceuticals, Inc; Eidos Therapeutics, Inc; SOM BIOTECH; Abbvie, Inc; Bausch Health Companies Inc; Bristol Myers Squibb Company; GSK Plc; Merck KGaA; Sanofi
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options